2022 / 03

Next Paper
DOI: 10.24075/medet.2022.055

REVIEW

Ethical issues of the off-label use of drugs for treatment of COVID-19

Severova YaG, Teplova NV
About authors

Pirogov Russian National Research Medical University, Moscow, Russia

Correspondence should be addressed: Yaroslavna G. Severova
Ostrovityanov ul. 1, Moscow, 117513, Russia; moc.liamg@ves.anvalsoray

About paper

Author contribution: Severova YaG developed the concept and the structure of the article, reviewed the literature and wrote the text; Teplova NV contributed to the article concept development, provided academic supervision, finalized the text and approved it before publishing.

Received: 2022-07-25 Accepted: 2022-08-26 Published online: 2022-11-29
|
  1. Website of the Coronavirus Control project. Available from: https:// coronavirus-control.ru Russian.
  2. Temporary guidelines «Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 16 (08/18/2022)». ConsultantPlus. Russian.
  3. World Health Organization (WHO). WHO best-practice statement on the off-label use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis. Available from: https://apps.who.int/iris/bitstream/handle/10665/258941/ WHO-HTM-TB-2017.20-eng.pdf.
  4. The Law of the Russian Federation «On Amendments to the Law of the Russian Federation “On the basics of public health protection in the Russian Federation”» dated 30.12.2021 No. 482. ConsultantPlus. Russian.
  5. Government Decree «On approval of the list of diseases or conditions (groups of diseases or conditions) in which the use of a medicinal product is allowed in accordance with the indicators (characteristics) of a medicinal product not specified in the Instructions for its use» dated 05/16/2022 No. 1180-r. ConsultantPlus. Russian.
  6. Dresser R, Frader J. Off-label prescribing: a call for heightened professional and government oversight. J Law Med Ethics. 2009; 37: 476–486, 396.
  7. Letter “On the issues of conducting clinical trials of medicines in the conditions of the COVID-19 coronavirus pandemic” dated 27.03.2020 No. 20–1/I/2–3651. Ministry of Health of the Russian Federation. Russian.
  8. Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial. Ann Intern Med. 2020; 173: 623–631.
  9. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 — final report. N Engl J Med. 2020; 383: 1813–1826.
  10. AlQahtani M, Kumar N, Aljawder D, Abdulrahman A, Wael MM, Alnashaba F, et al. Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/ moderate COVID-19 disease. Sci Rep. 2022 Mar 23; 12 (1): 4925.
  11. Bosaeed M, Alharbi A, Mahmoud E, Alrehily S, Bahlaq M, Gaifer Z, et al. Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial. Clin Microbiol Infect. 2022 Apr; 28 (4): 602–608.
  12. Vidal’s reference site «Medicines in Russia». Available from: http://www.vidal.ru Russian.